EGF-genistein conjugates for the treatment of cancer

Details EGF-genistein conjugates for the treatment of cancer EGF-genistein conjugates for the treatment of cancer

1996-02-16

1999-06-15

Huff, Sheela

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

4241851, 4241921, 4241931, 5303917, 514 2, 514 4, A61K 39385, A61K 3900, C07K 1600, A01N 6100

Patent

active

059119950

ABSTRACT:
A conjugate formed of epidermal growth factor covalently linked to a tyrosine kinase inhibitor, such as genistein, and a method for killing cancer cells, in vivo and in vitro, by administering a cytotoxic dose of an epidermal growth factor tyrosine kinase inhibitor conjugate.

REFERENCES:
patent: 5587459 (1996-12-01), Uckun
Emmis BW. Cancer Investigation 9(5): 553-562,1991.
Lyall RM et al Cancer Research 47: 2961-2966, 1987.
Abrams, et al. Cancer 74(3 Supp):1164-76 (1994).
Adlercreutz, et al. Am. J. Clin. Nutr. 54: 1093-1100 (1991).
Adlercreutz, et al. Lancet, 342, 1209 (1993).
Arteaga, et al. Cancer Res. 54:4703-09 (1994).
Aullo et al. The EMBO Journal, 11(2), 575-583 (1992).
Avila et al. Cancer Res., 54:2424-2428 (1994).
Baselga et al. Breast Cancer Res. and Treatment, 29:127-138 (1994).
Baselga et al. J. Nat'l Cancer Inst., 85:1327-33 (1993).
Batra et al. Proc. Nat. Acad. Sci. USA, 89, 5867-5871 (Jul. 1992).
Batra et al. The Journal of Biological Chemistry, 265(25), 15198-15202 (Sep. 5, 1990).
Bennett et al. PNAS USA, 91, 3127 (1994).
Berchuch et al. Am. J. Obest. Gynec., 164:669-674 (1991).
Bolen et al. Adv. Can Res., 57, 103 (1991).
Bolen Cell Growth & Diff., 2:409-414 (Aug. 1991).
Bolen et al. FASEBJ, 6:3403-7 (Dec. 1992).
Bolognesi et al. Clin. Exp. Immunol. 89, 341 (1992).
Bonadonna et al. JAMA, 273:542-7 (Feb. 1995).
Campbell et al. EMBO J., 9, 2125 (1990).
Canevari et al. Annals. of Oncology, 5, 698-701 (1994).
Carpenter et al. J. Biol. Chem., 265:7709-12 (1990).
Chal et al. Cancer Res., 53:447-451 (Feb. 1993).
Ching et al. Mol. Cell Biochem., 126:151-158 (1993).
Chrysogelos et al. Breast Cancer Res. & Tmt., 29:29-40 (1994).
Clavel et al. Eur. J. Cancer, 29A-598-604 (1993).
Cohen et al. J. Urology, 152:2120-2124 (Dec. 1994).
Connolly et al. The Prostate, 20:151-158 (1992).
Constantinou et al. Cancer Res., 50, 2618 (1990).
Cushman et al. J. Med. Chem., 37:3353-3362 (1994).
Cushman et al. J. Med. Chem., 34:798-806 (1991).
Dean et al. Int. J. Cancer, 8:103-107 (1994).
deWit et al. JI Investig. Dermatology, 99:168-173 Aug. 1992).
Dunphy et al. Cancer, 73:2157-67 (Apr. 1994).
Embleton et al. Br. J. Cancer, 63, 670-674 (1991).
Fong et al. Cancer Res. 52:5887-5892 (Nov. 1992).
Fox et al. Breast Cancer Res. & Tmt., 29:41-9 (1994).
Fu et al. Cardiovascular Research, 27, 1691-1697 (1993).
Fukuzawa et al. Biochem. Pharmacol., 42, 1661-1671 (1991).
Gasparini et al. Breast Cancer Res. & Tmt., 29:59-71 (1994).
Gorgoulis et al. AntiCancer Res., 12:1183-88 (1992).
Gottstein et al. Annals of Oncology, 5, S97 (1994).
Grossbard et al. Important Advances in Oncology, pp. 112-136 (1992).
Grossbard et al., "Immunotoxin Therapy of Malignancy", pp. 111-131, 1989.
Gullick Br. Med. Bull., 47:87-98 (1991).
Gunther et al. Leukemia, 7:298-309 (Feb. 1993).
Harris Cancer Cells, 2(10), 321-323 (Oct. 1990).
Heimbrook et al. Journal of Industrial Microbiology, 7, 203-208 (1991).
Hertler et al. J. Clin. Oncol., 7, 1932 (1989).
Hirono et al. Oncology, 52:182-188 (1995).
Holting et al. E.J. Endocrinology, 132-229-35 (1995).
Honma et al. Cancer Res., 52:4017-4020 (Jul. 1992).
Houston et al. Immunoconjugates, Antibody-Conjugates in Radioimaging and Therapy of Cancer, pp. 71-96 (1987).
Hunter et al. Annu. Rev. Biochem., 54, 897 (1985).
Huston et al. Intern. Rev. Immunol., 10, 195-217 (1993).
Hwu et al. The Journal of Experimental Medicine, 178, 361-366 (Jul. 1993).
Irvin et al. Meeting Abstract, International Association for Comparative Research on Leukemia and Related Diseases, 16th Symposium Jul. 11-16, 1993, Montreal, Quebec, Canada.
Kersey et al. Abstract of presentation at symposium to Honor. G. and E. Klein, Omaha, NE, May 1991.
Khazaie et al. Cancer & Metastasis Revs., 12:255-74 (1993).
Kirk et al. Br. J. Cancer, 69:988-994 (1994).
Klijn et al. Cancer Res. & Treat., 29:73-83 (1994).
Lee et al. Protein Engineering, 6(4), 433-440 (1993).
Lipponen Br. J. Cancer, 69:1120-1124 (1994).
Lorberboum-Galski et al. The Journal of Biological Chemistry 263(35), 18650-56 (Dec. 15, 1988).
Markovits et al. 21st Ann. Mtg. Am. Assoc. Cancer Res., May 23-26, 1990, Wash, D.C.
Maygarden et al. Modern Pathology, 7:930-936 1994).
Mendelsohn et al. In: Biologic Therapy of Cancer: Principles and Practice, pp. 607-623 (1995).
Mendelsohn J. Nat'l Cancer Inst., 13:125-131 (1992).
Mesri et al. The Journal of Biological Chemistry, 268(7), 4853-4862 (Mar. 5, 1993).
Modjtahedi et al. Br. J. Cancer, 67:254-261 (1993).
Mueller et al. Cancer Res., 51:2193-98 (1991).
Mukaida et al. Cancer, 68:142-148 (1991).
Muthuswany et al. Mol. Cell Biol., 14:735-743 (Jan. 1994).
Naramura Cancer Immunol. Immunother., 37:343-349 (1993).
Okabe et al. Blood, 80:1330-1338 (Sep. 1992).
Okabe et al. Leukemia & Lymphoma, 12:41-49 (1993).
Otani et al. J. Biol. Chem., 268, 22733 (Oct. 21, 1993).
Ottenhoff-Kalff et al. Cancer Res., 52:4773-8 (Sep. 1992).
Pai et al. Cancer Research, 51, 2808-2812 (Jun. 1, 1991).
Pastan et al. Cell, 47, 641 (1986).
Pastan et al. Science, 254, 1173-1177 (Nov. 22, 1991).
Pastan et al. The Journal of Biological Chemistry, 264(26), 15157-15160 (Sep. 15, 1989).
Pelham et al. Eur. J. Biochem., 67, 247 (1976).
Perentesis et al. Abstract AI-00793 (Sep. 1, 1987).
Perentesis et al. Abstract CA-53586 (Mar. 1, 1993).
Perentesis et al. Biofactors, 3 (1991/92).
Perentesis et al. PNAS USA, 85, 8386 (1988).
Pickering et al. J. Clin. Invest., 91, 724-729 (Feb. 1993).
Piontek et al. AntiCancer Res., 13:2119-2124 (1993).
Scheuermann et al. PNAS USA, 91, 4048-4052 (1994).
Schnurch et al. E. J. Cancer, 30A:491-496 (1994).
Scholar et al. Cancer Letters, 87:159-162 (1992).
Shaw et al. The Journal of Biological Chemistry, 266(31), 21118-21124 (Nov. 5, 1991).
Spinozzi et al. Leuk. Res., 18, 431 (1994).
Takekara et al. Int. J. Cancer, 47:938-942 (1991).
Theuer et al. Journal Biolog. Chemistry, 267(24), 16872-16877 (Aug. 25, 1992).
Thomas Drugs of Today, 28:311-331 (1992).
Toi et al. Eur. J. Cancer, 26:722-724 (1990).
Traganos et al. Cancer Res., 52, 6200 (1992).
Trail, et al. Science 261:212 (Jul. 1993).
Uckun Antibody Immunoconjugates and Radiopharmaceutics, 1, 247 (1988).
Uckun et al. Blood, 71 13 (1988).
Uckun Brit. J. Haematol., 85, 435 (Nov. 9, 1993).
Uckun Grant No. 1U01CA61549-01--B43(Anti-CD19)-Pokeweed Antiviral Protein Immunotoxin (1994).
Uckun et al. Int. J. Radiat. Biol., 56, 611-615 (1989).
Uckun et al. J. Immunol., 134, 2010 (1985).
Uckun et al. Leukemia, 7, 341 (Feb. 1993).
Uckun et al. PNAS USA, 90, 252 (Jan. 1993).
Ullrich et al. Cell, 61:203-212 (Apr. 1990).
Vitetta et al. Biologic Therapy of Cancer, pp. 482-495 (1991).
Vitetta et al. Cancer Res., 51, 4052-4058 (Aug. 1, 1991).
Vietta, et al. Science 225:1098-1104 (1984).
Wada et al. Cancer Research, 48, 2273 (1988).
Wingo et al. A Cancer J. for Clinicians, 45, 8-30 (Jan./Feb. 1995).
Yamanashi et al. Science, 251:192-194 (Jan. 1991).

Affiliated with

Also associated with

Rating

EGF-genistein conjugates for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EGF-genistein conjugates for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EGF-genistein conjugates for the treatment of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-400979